{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-021093","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.941572+00:00","generated_at":"2026-05-18T22:34:01.963872+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Genprex reports positive preclinical data for diabetes gene therapy GPX-002 at ADA","bullets":["Alpha cells in Type 1 diabetes mouse models transdifferentiated to insulin-secreting beta-like cells after GPX-002 infusion.","In diabetic non-human primates, GPX-002 improved glucose tolerance and reduced insulin requirements at one month post-infusion.","Three-month immunosuppression with rituximab, rapamycin, and steroids largely prevented anti-viral immunity in NHPs.","Continued studies will evaluate GPX-002 efficacy after six months of immunosuppression in NHP models."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-021093","json":"https://secwatch.observer/filing/0001437749-25-021093.json","markdown":"https://secwatch.observer/filing/0001437749-25-021093.md","text":"https://secwatch.observer/filing/0001437749-25-021093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925021093/0001437749-25-021093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925021093/gnpx20250618c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:34:01.963872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}